Highlight
The AS01E-adjuvanted RSV prefusion F protein vaccine (RSVPreF3 OA) showed 62.9% cumulative efficacy against RSV-related lower respiratory tract disease (RSV-LRTD) over three consecutive respiratory syncytial virus (RSV) seasons in adults aged 60 years and above.
Both single-dose and revaccination after one year demonstrated comparable efficacy profiles, although efficacy gradually decreased over time.
